Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Luspatercept in Myeloproliferative Neoplasm-Associated Myelofibrosis with Anemia
2017-000322-35Phase 2Unknown
- Sponsor
- Celgene Corporation
- Start
- Jun 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in primary myelofibrosis (PMF), myelofibrosis (MF) and anaemia, sponsored by Celgene Corporation. Primary endpoint: Anemia response as hemoglobin increase. Status: unknown.
02
Drugs
luspatercept
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)anaemia
Beyond the preview
Go deeper on 2017-000322-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000322-35.